Stock Scorer

Revolution Medicines, Inc. (RVMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 6M 12M 18M Q1 '20: 11.5M Q2 '20: 10M Q3 '20: 12.7M Q4 '20: 8.8M Q1 '21: 10.1M Q2 '21: 8.7M Q3 '21: 1.1M Q4 '21: 9.5M Q1 '22: 7.6M Q2 '22: 9.1M Q3 '22: 3.4M Q4 '22: 15.3M Q1 '23: 7M Q2 '23: 3.8M Q3 '23: 0 Q4 '23: 742K Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating Income Quarterly

-600M -400M -200M 0 200M 400M 600M Q3 '21: -53.2M Q4 '21: -52.9M Q1 '22: -57.9M Q2 '22: -62.1M Q3 '22: -76.5M Q4 '22: -61.7M Q1 '23: -75.2M Q2 '23: -108.8M Q3 '23: -123.2M Q4 '23: -180M Q1 '24: -140.9M Q2 '24: -156.6M Q3 '24: -175.7M Q4 '24: -216.3M Q1 '25: -240.8M Q2 '25: -264.7M Q3 '25: -315.3M Q4 '25: -361.6M Q1 '26: -445.2M Q2 '26: -505.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '21: -52.9M Q4 '21: -52.7M Q1 '22: -57.6M Q2 '22: -61.2M Q3 '22: -73.3M Q4 '22: -56.5M Q1 '23: -68.1M Q2 '23: -98.3M Q3 '23: -108.4M Q4 '23: -161.5M Q1 '24: -116M Q2 '24: -133.2M Q3 '24: -156.3M Q4 '24: -194.6M Q1 '25: -213.4M Q2 '25: -247.8M Q3 '25: -305.2M Q4 '25: -364.9M Q1 '26: -453.8M Q2 '26: -644.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-450M -300M -150M 0 150M 300M 450M Q3 '21: -36.6M Q4 '21: -39.3M Q1 '22: -55.2M Q2 '22: -55.7M Q3 '22: -51.7M Q4 '22: -61.8M Q1 '23: -62.4M Q2 '23: -67.1M Q3 '23: -100.5M Q4 '23: -120.6M Q1 '24: -160.6M Q2 '24: -128.2M Q3 '24: -130.4M Q4 '24: -138.3M Q1 '25: -194.4M Q2 '25: -221.8M Q3 '25: -207.3M Q4 '25: -274.2M Q1 '26: -354.2M Q2 '26: -387.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-450M -300M -150M 0 150M 300M 450M Q3 '21: -37M Q4 '21: -40.4M Q1 '22: -57M Q2 '22: -58.2M Q3 '22: -55.3M Q4 '22: -64.7M Q1 '23: -64.1M Q2 '23: -68.2M Q3 '23: -103M Q4 '23: -122.9M Q1 '24: -163.7M Q2 '24: -130.6M Q3 '24: -133.9M Q4 '24: -139.5M Q1 '25: -197.7M Q2 '25: -229.2M Q3 '25: -210.7M Q4 '25: -276.2M Q1 '26: -355.7M Q2 '26: -389.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q2 '21: 73.4M Q3 '21: 73.5M Q1 '22: 74.2M Q2 '22: 74.3M Q3 '22: 84.7M Q1 '23: 94.8M Q2 '23: 106.9M Q3 '23: 109.2M Q1 '24: 164.7M Q2 '24: 165.1M Q3 '24: 166.8M Q1 '25: 188.1M Q2 '25: 188.6M Q3 '25: 189.2M Q1 '26: 198.1M Q2 '26: 210.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q3 '21: -2.37 Q4 '21: -2.57 Q1 '22: -2.82 Q2 '22: -3.04 Q3 '22: -3.19 Q4 '22: -3.08 Q1 '23: -3.02 Q2 '23: -3.12 Q3 '23: -3.24 Q4 '23: -3.84 Q1 '24: -3.82 Q2 '24: -3.71 Q3 '24: -3.66 Q4 '24: -3.58 Q1 '25: -4.01 Q2 '25: -4.51 Q3 '25: -5.18 Q4 '25: -5.94 Q1 '26: -7.10 Q2 '26: -8.85 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for RVMD: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.